论文部分内容阅读
作者对76例系统性红斑狼疮(SLE)和44例盘状红斑狼疮(DLE)患者进行了DNCB致敏作用的研究,以101例接受免疫抑制剂治疗的病人和肿瘤患者,40例接触过敏性湿疹和115例未经选择的各种皮肤病患者作为对照。结果:76例SLE中的44例(58%)和44例DLE中的32例(73%)能被致敏。101例有免疫抑制的阴性对照者中的24例,以及40例对多种物质敏感的阳性对照者中的32例(80%)亦被致敏。在115例未经选择的患者中,有85例(73%)被致敏。在76例SLE患者中的19例(25%)和44例DLE患者中的19例(43%),出现同形反应。SLE的同形反应出现于应用DNCB后的第13～15天,DLE的同形反应显现于第19～20天。肉眼观察见接触DNCB的部位显示红斑狼疮的
The authors studied the sensitization of 76 patients with systemic lupus erythematosus (SLE) and 44 patients with discoid lupus erythematosus (DLE) to 101 patients with immunosuppressive agents and tumors and 40 patients with allergic contact Eczema and 115 cases of various skin diseases without the control as a control. RESULTS: Forty-four of the 76 SLE patients (58%) and 44 of 44 DLE patients (73%) were sensitized. Twenty-four (80%) of the 101 immunosuppressed negative controls were also sensitized, as were 40 of the 40 positive controls that were sensitive to multiple substances. Of the 115 unselected patients, 85 (73%) were sensitized. Nineteen (25%) of 76 patients with SLE and 19 (44%) of 44 patients with DLE developed a homomorphic response. The isomorphic response of SLE occurred on the 13th to 15th days after the application of DNCB. The isomorphic response of DLE appeared on the 19th to 20th day. Macroscopic observation of the site of exposure to DNCB showed lupus